Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Increased to Strong-Buy at Zacks Research

Key Points

• Zacks Research has upgraded Ironwood Pharmaceuticals (NASDAQ:IRWD) from a "hold" to a "strong-buy" rating, suggesting increased confidence in the company’s stock.
• Ironwood Pharmaceuticals reported earnings of $0.14 per share, surpassing analysts' expectations significantly, with revenues for the quarter also exceeding projections at $85.24 million.
• Institutional investors are actively increasing their stakes in Ironwood, with notable increases from firms like Acadian Asset Management and Voleon Capital Management during the first quarter.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) was upgraded by research analysts at Zacks Research from a "hold" rating to a "strong-buy" rating in a report issued on Monday,Zacks.com reports.

Several other brokerages have also recently weighed in on IRWD. Wall Street Zen upgraded Ironwood Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday, August 9th. Weiss Ratings restated a "sell (e+)" rating on shares of Ironwood Pharmaceuticals in a research report on Saturday, September 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, Ironwood Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $4.94.

Ironwood Pharmaceuticals Stock Up 2.7%

Shares of NASDAQ IRWD opened at $1.52 on Monday. The firm has a market cap of $246.89 million, a PE ratio of -30.39 and a beta of 0.30. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.13. The business has a 50 day moving average price of $1.19 and a two-hundred day moving average price of $0.95.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last issued its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative return on equity of 2.46% and a negative net margin of 2.25%.The business had revenue of $85.24 million for the quarter, compared to analysts' expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts anticipate that Ironwood Pharmaceuticals will post 0.1 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of IRWD. Acadian Asset Management LLC boosted its position in shares of Ironwood Pharmaceuticals by 160.7% in the first quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company's stock worth $3,878,000 after purchasing an additional 1,630,726 shares during the period. Voleon Capital Management LP increased its stake in Ironwood Pharmaceuticals by 952.4% in the 1st quarter. Voleon Capital Management LP now owns 870,629 shares of the biotechnology company's stock worth $1,280,000 after buying an additional 787,901 shares during the period. GSA Capital Partners LLP grew its holdings in Ironwood Pharmaceuticals by 3,683.6% during the 1st quarter. GSA Capital Partners LLP now owns 524,676 shares of the biotechnology company's stock worth $771,000 after acquiring an additional 510,809 shares in the last quarter. Inspire Investing LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 159.7% in the 1st quarter. Inspire Investing LLC now owns 231,825 shares of the biotechnology company's stock valued at $341,000 after buying an additional 142,574 shares in the last quarter. Finally, Pallas Capital Advisors LLC raised its position in shares of Ironwood Pharmaceuticals by 454.5% in the 2nd quarter. Pallas Capital Advisors LLC now owns 79,512 shares of the biotechnology company's stock valued at $57,000 after purchasing an additional 65,172 shares during the last quarter.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.